FDA rejects Ultragenyx's Sanfilippo gene therapy over manufacturing issues

The FDA hit Ultragenyx with a complete response letter for its AAV gene therapy, called UX111, over manufacturing issues. However, the company believes those issues can be solved and that the therapy can be approved ...